Early versus delayed follow-up after misoprostol treatment for early pregnancy loss.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 18 11 2018
revised: 15 01 2019
accepted: 25 02 2019
pubmed: 27 4 2019
medline: 5 8 2020
entrez: 27 4 2019
Statut: ppublish

Résumé

Does extending the follow-up after misoprostol treatment for early pregnancy loss increase the success rate? Patients who had experienced early pregnancy loss (<12 weeks) and were treated with misoprostol in a single university-affiliated medical centre were prospectively followed before and after the implementation of a new treatment protocol extending the follow-up from 1 to 2 weeks. All patients received misoprostol 800 μg vaginally on day 1 and a second dose, when needed, on day 4 or 8. Patients underwent surgical aspiration after 1 week in the early follow-up group (n = 84) or 2 weeks in the delayed follow-up group (n = 85) if complete expulsion was not achieved (defined as endometrial thickness ≤15 mm and absence of gestational sac on transvaginal sonography). The primary outcome was treatment success, defined as no need for surgical aspiration. Women in the delayed follow-up group had a higher rate of successful treatment compared with women in the early follow-up group (88.2% versus 76.2%, respectively; P = 0.040), and a lower rate of second dose administration (32.9% versus 51.2%, respectively; P = 0.016). The incidence of non-expulsion of the gestational sac was also lower in the delayed follow-up group (1.2% versus 10.7%; P = 0.009). Treatment acceptability did not differ between the study groups. In women with early pregnancy loss treated with misoprostol, extending the follow-up protocol from 1 to 2 weeks resulted in an increase in treatment success.

Identifiants

pubmed: 31023610
pii: S1472-6483(19)30237-8
doi: 10.1016/j.rbmo.2019.02.011
pii:
doi:

Substances chimiques

Misoprostol 0E43V0BB57

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155-160

Informations de copyright

Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Yossi Mizrachi (Y)

Department of Obstetrics and Gynecology, the Edith Wolfson Medical Center, 62 Ha-Lokhamim St POB 58100, Holon, Israel(1). Electronic address: mizrachi.yossi@gmail.com.

Liliya Tamayev (L)

Department of Obstetrics and Gynecology, the Edith Wolfson Medical Center, 62 Ha-Lokhamim St POB 58100, Holon, Israel(1).

Ofer Shemer (O)

Department of Obstetrics and Gynecology, the Edith Wolfson Medical Center, 62 Ha-Lokhamim St POB 58100, Holon, Israel(1).

Ilia Kleiner (I)

Department of Obstetrics and Gynecology, the Edith Wolfson Medical Center, 62 Ha-Lokhamim St POB 58100, Holon, Israel(1).

Jacob Bar (J)

Department of Obstetrics and Gynecology, the Edith Wolfson Medical Center, 62 Ha-Lokhamim St POB 58100, Holon, Israel(1).

Ron Sagiv (R)

Department of Obstetrics and Gynecology, the Edith Wolfson Medical Center, 62 Ha-Lokhamim St POB 58100, Holon, Israel(1).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH